DK2704741T3 - Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler - Google Patents

Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler

Info

Publication number
DK2704741T3
DK2704741T3 DK12779413.9T DK12779413T DK2704741T3 DK 2704741 T3 DK2704741 T3 DK 2704741T3 DK 12779413 T DK12779413 T DK 12779413T DK 2704741 T3 DK2704741 T3 DK 2704741T3
Authority
DK
Denmark
Prior art keywords
methods
live cells
containing live
handling biological
medicinals containing
Prior art date
Application number
DK12779413.9T
Other languages
Danish (da)
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Application granted granted Critical
Publication of DK2704741T3 publication Critical patent/DK2704741T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/148—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
DK12779413.9T 2011-05-03 2012-05-02 Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler DK2704741T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161481991P 2011-05-03 2011-05-03
US201161528493P 2011-08-29 2011-08-29
US201161565225P 2011-11-30 2011-11-30
US201261582878P 2012-01-04 2012-01-04
PCT/US2012/036103 WO2012151266A1 (en) 2011-05-03 2012-05-02 Methods for handling biological drugs containing living cells

Publications (1)

Publication Number Publication Date
DK2704741T3 true DK2704741T3 (da) 2017-11-27

Family

ID=47108026

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12779413.9T DK2704741T3 (da) 2011-05-03 2012-05-02 Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler

Country Status (17)

Country Link
US (4) US10350242B2 (https=)
EP (1) EP2704741B1 (https=)
JP (3) JP5934783B2 (https=)
KR (3) KR20140099328A (https=)
CN (2) CN103732247A (https=)
AU (1) AU2012250794B2 (https=)
BR (1) BR112013028257B1 (https=)
CA (1) CA2838041C (https=)
DK (1) DK2704741T3 (https=)
ES (1) ES2648136T3 (https=)
HU (1) HUE034995T2 (https=)
IL (1) IL229176B (https=)
PH (1) PH12013502253A1 (https=)
PL (1) PL2704741T3 (https=)
PT (1) PT2704741T (https=)
SG (1) SG194774A1 (https=)
WO (1) WO2012151266A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095307A1 (en) * 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
JP6814593B2 (ja) * 2016-10-14 2021-01-20 株式会社 バイオミメティクスシンパシーズ 幹細胞及び投与システム
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
KR20210125986A (ko) * 2018-12-07 2021-10-19 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 면역요법을 위한 조성물 및 방법
TW202110463A (zh) * 2019-05-15 2021-03-16 美商永生生技股份有限公司 高濃度細胞包裝和運送
EP4261242A4 (en) 2020-12-10 2024-11-06 Agc Inc. OXYALKYLENE POLYMER, PROCESS FOR PRODUCING SAME, CURABLE COMPOSITION AND CURED PRODUCT
EP4306570A4 (en) 2021-03-12 2025-03-05 Agc Inc. HARDENABLE COMPOSITION AND HARDENED PRODUCT
WO2023282298A1 (ja) 2021-07-07 2023-01-12 Ａｇｃ株式会社 硬化性組成物、硬化物、接着剤、及びシーリング材
JPWO2023190640A1 (https=) * 2022-03-30 2023-10-05
WO2023204067A1 (ja) 2022-04-22 2023-10-26 Ａｇｃ株式会社 硬化性組成物及びその硬化物
JPWO2023204064A1 (https=) 2022-04-22 2023-10-26
WO2023210586A1 (ja) 2022-04-27 2023-11-02 Ａｇｃ株式会社 反応性ケイ素基含有有機重合体の製造方法
EP4516821A4 (en) 2022-04-27 2026-04-29 Agc Inc PROCESS FOR PRODUCING AN ORGANIC POLYMER CONTAINING A REACTIVE SILICON GROUP
CN119301211A (zh) 2022-06-03 2025-01-10 Ａｇｃ株式会社 粘接剂组合物及物品
WO2026009590A1 (ja) 2024-07-05 2026-01-08 Ａｇｃ株式会社 複合金属シアン化物錯体触媒、ポリエーテル化合物の製造方法、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法、及び重合性不飽和基を有するポリエーテル化合物の製造方法
WO2026009589A1 (ja) 2024-07-05 2026-01-08 Ａｇｃ株式会社 組成物、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法、及び重合性不飽和基を有するポリエーテル化合物の製造方法
WO2026014465A1 (ja) 2024-07-12 2026-01-15 Ａｇｃ株式会社 ポリエーテル化合物の製造方法、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法及び重合性不飽和基を有するポリエーテル化合物の製造方法
EP4737503A1 (en) 2024-07-12 2026-05-06 Agc Inc. Method for producing polyether compound, method for producing polyether compound having reactive silicon group, method for producing polyether compound having urethane bond, and method for producing polyether compound having polymerizable unsaturated group
EP4711399A1 (en) 2024-07-12 2026-03-18 Agc Inc. Method for producing polyether compound, method for producing polyether compound having reactive silicon group, method for producing polyether compound having urethane bond, and method for producing polyether compound having polymerizable unsaturated group

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
WO1994012196A1 (en) 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2214649C (en) 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
ES2278390T3 (es) 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
CA2274004A1 (en) 1996-12-03 1998-06-11 Osteobiologics, Inc. Biodegradable polymeric film
CA2278847A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
ATE412383T1 (de) 1997-05-30 2008-11-15 Osteobiologics Inc Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung
CA2309206A1 (en) 1997-11-10 1999-05-20 Arch Development Corporation Methods for treatment of tumors and tumor cells using ex vivo activated t cells
AU4518400A (en) 1999-07-12 2001-01-18 Isotis B.V. Sutures
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US20020127208A1 (en) 2000-08-31 2002-09-12 Waller Edmund K. Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
WO2003038062A2 (en) 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells
WO2003053216A2 (en) 2001-12-06 2003-07-03 University Of Washington Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
CA2555714C (en) 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
DK1749090T3 (en) 2004-03-01 2017-09-04 Immunovative Therapies Ltd CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION
US20060036331A1 (en) 2004-03-05 2006-02-16 Lu Helen H Polymer-ceramic-hydrogel composite scaffold for osteochondral repair
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP1792979A1 (en) 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
RU2496482C2 (ru) * 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств

Also Published As

Publication number Publication date
US10350242B2 (en) 2019-07-16
PT2704741T (pt) 2017-11-24
BR112013028257B1 (pt) 2020-05-12
CN108261423A (zh) 2018-07-10
WO2012151266A1 (en) 2012-11-08
CN103732247A (zh) 2014-04-16
PH12013502253A1 (en) 2019-11-29
HK1254754A1 (zh) 2019-07-26
IL229176B (en) 2020-03-31
JP6359059B2 (ja) 2018-07-18
CN108261423B (zh) 2021-01-08
US20230226112A1 (en) 2023-07-20
US20230218672A1 (en) 2023-07-13
ES2648136T3 (es) 2017-12-28
CA2838041C (en) 2018-09-25
JP2017039728A (ja) 2017-02-23
AU2012250794B2 (en) 2015-11-05
US20130101562A1 (en) 2013-04-25
SG194774A1 (en) 2013-12-30
KR102202460B1 (ko) 2021-01-14
AU2012250794A8 (en) 2013-12-19
BR112013028257A2 (pt) 2017-01-17
AU2012250794A1 (en) 2013-12-12
KR20140043367A (ko) 2014-04-09
PL2704741T3 (pl) 2018-02-28
IL229176A0 (en) 2013-12-31
CA2838041A1 (en) 2012-11-08
US20190350976A1 (en) 2019-11-21
JP2014517830A (ja) 2014-07-24
KR20140099328A (ko) 2014-08-11
HUE034995T2 (en) 2018-05-02
EP2704741A4 (en) 2014-11-19
KR102229108B1 (ko) 2021-03-18
EP2704741A1 (en) 2014-03-12
JP2015091848A (ja) 2015-05-14
JP5934783B2 (ja) 2016-06-15
JP6006288B2 (ja) 2016-10-12
KR20190090030A (ko) 2019-07-31
EP2704741B1 (en) 2017-08-23
US11648273B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
DK2704741T3 (da) Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler
CL2016001190A1 (es) Cultivo de células de mamífero.
EP2681306A4 (en) CELL CULTURE SYSTEM
DK2539707T3 (da) Kunstige mycolsyremembraner
EP2630158A4 (en) Discovery of regulatory t cells programmed to suppress an immune response
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
IL263479B (en) Virus filtration of cell culture media
DK2882850T3 (da) System for preparation of adipose-derived stem cells
EP2777276A4 (en) Reference picture handling
EP3375462C0 (en) Improvements to immobilised biological entities
IT1404521B1 (it) Gruppo contenitore
DK2893001T3 (da) Fremgangsmåde til dyrkning af mesenkymale stamceller
BR112013012217A2 (pt) incubadora
DK2817406T3 (da) Engangsseparator til tilbageholdelse og tilbageføring af celler
DK2569438T3 (da) Fremgangsmåde til fremstilling af biogas
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
DK2782565T3 (da) Anvendelse af aryl- og hetarylcarboxamider som endoparasiticider
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK3399019T3 (da) Fremgangsmåder til bevaring af kulturs levedygtighed
FR2955483B1 (fr) Cage intersomatique
FR2981262B1 (fr) Implant intersomatique
DK2802204T3 (da) Modulering af plantebiologi
EP2622089C0 (en) DEMANNOSYLATION OF PHOSPHORYLATED N-GLYCANS
DK2606116T3 (da) Bioreaktorsystem
DK2825633T3 (da) Fremgangsmåde til dyrkning af E. coli-celler til høj densitet